MAPT and early-onset autosomal dominant Alzheimer disease: Given that the LC-NE system is intimately involved in the therapeutic effects of VNS, and likely improves cognition via norepinephrine release and improved executive performance, it is notable that the earliest stages of pathological tau accumulation in Alzheimer’s disease are seen in the LC.